JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

"Conflict of interest Tetsuo Takehara has received an honorarium and a research grant from Janssen. Kazuaki Chayama has received honoraria from AbbVie, Bristol-Myers Squibb, Chugoku Electric Power, Dainippon Sumitomo, Eisai, Gilead Sciences, Mitsubishi Tanabe, MSD, and Otsuka and research grants from AbbVie, Bristol-Myers Squibb, Chugoku Electric Power, Daiichi Sankyo, Dainippon Sumitomo, EA Pharma, Eisai, Mochida Pharmaceutical, MSD, Nippon Kayaku, Otsuka, Roche, Takeda, and Toray. Masayuki Kurosaki, Naoki Hiramatsu, and Norio Hayashi have no conflicts of interest to declare. Hiroshi Yatsuhashi has received a research grant from AbbVie. Yasuhito Tanaka has received an honorarium from Gilead Sciences and research grants from Chugai Pharmaceutical Co. Ltd., Gilead Sciences and Janssen. Naoya Sakamoto has received honoraria from AbbVie, ASKA Pharmaceutical Co. Ltd., Asuka Pharmaceutical Co. Ltd., Eisai, Gilead Sciences, MSD and Otsuka Pharmaceuticals, and research grants from AbbVie, Chugai Pharmaceutical Co. Ltd., Gilead Sciences, MSD, Otsuka Pharmaceuticals, Shonogi, and Takeda. Yasuhiro Asahina belongs to a donation-funded department, funded by AbbVie GK, Chugai Pharmaceutical Co. Ltd., Fujirebio Inc., Gilead Sciences, MSD, and Toray Industries Inc. Akito Nozaki has received research grants from AbbVie GK and Gilead Sciences. Toshikazu Nakano, Yosuke Hagiwara, Hiroko Shimizu, and Hiroki Yoshida are employees of Janssen Pharmaceutical K.K. Yuhan Huang is an employee of Janssen (China) Research and Development, LLC. Michael Biermer and Leen Vijgen are employees of Janssen Pharmaceutica NV and shareholders of Johnson & Johnson."

"Funding This study was funded by Janssen Pharmaceutical K.K."